Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Boehringer Bails On Biosimilars Outside US

Dec 04 2018

• By Kevin Grogan

Statue of Liberty — US is land of opportunity for BI biosimilar • Source: Shutterstock

Related Content

Enthusiasm For US Biosimilars Wanes For Some, But Not Others

Aug 15 2018

Momenta Is Exiting Biosimilars; Is That A Bellwether For Biosimilar Sentiment?

Oct 02 2018

AbbVie Inks Sixth Humira Biosimilar Settlement, Battles Boehringer's 'Unclean Hands' Claim

Nov 09 2018

Pfizer Decides Not To Challenge AbbVie's Humira Biosimilar Patents

Dec 01 2018

Keeping Track: US FDA Enters Year's Final Stretch With Tsunami Of Novel Approvals

Dec 01 2018

Humira Under Pressure As NHS England Invites 'Competitive Prices' For Biosimilars

Oct 17 2018

Fresenius Covers All Bases With Akorn Acquisition And Merck Biosimilar Buy

Apr 25 2017

Related Companies

Boehringer Ingelheim GmbH

AbbVie Inc.

Pfizer Inc.

Amgen, Inc.

Samsung Bioepis Co., Ltd.

Viatris Inc.

Novartis AG

Fresenius SE & Co. KGaA

Momenta Pharmaceuticals, Inc.

Roche Holding AG

Teva Pharmaceutical Industries Ltd.

Celltrion, Inc.

Coherus Oncology, Inc.

Additional Topics

United States Biosimilars Business Strategies Legal Issues Commercial Immune Disorders BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window